News
AACR: cancer vaccine combination shows clinical activity in advanced solid tumors
According to an industry-funded, preliminary clinical trial presented at the AACR Virtual Annual Meeting currently underway, a personalized cancer vaccine in combination with the PD-L1 inhibitor atezolizumab appears to be well tolerated and to show modest clinical benefit in patients with advanced solid malignancies. “Many cancers are able to successfully avoid the immune system, and […]
